BiotechTube

IO102/IO103 + Nivolumab-Relatlimab

Phase 2Active
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Melanoma

Conditions

Melanoma

Trial Timeline

Jun 9, 2023 → Jun 9, 2027

NCT ID
NCT05912244

About IO102/IO103 + Nivolumab-Relatlimab

IO102/IO103 + Nivolumab-Relatlimab is a phase 2 stage product being developed by IO Biotech for Melanoma. The current trial status is active. This product is registered under clinical trial identifier NCT05912244. Target conditions include Melanoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05912244Phase 2Active

Competing Products

20 competing products in Melanoma

See all competitors
ProductCompanyStageHype Score
Binimetinib Oral TabletBiotrialPhase 1
25
Tasisulam-sodium + PaclitaxelEli LillyPhase 3
77
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
25
FYB206 + KeytrudaFormycon AGPhase 1
25
PLX3397Daiichi SankyoPre-clinical
23
PLX3397 + PembrolizumabDaiichi SankyoPhase 1/2
41
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
DS-8273a + NivolumabDaiichi SankyoPhase 1
33
PLX3397 + vemurafenibDaiichi SankyoPhase 1
33
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
CP-461Astellas PharmaPhase 2
52
YM155Astellas PharmaPhase 2
52
YM155 + DocetaxelAstellas PharmaPhase 2
52
Denileukin diftitoxEisaiPhase 2
52
E7080EisaiPhase 1
33
lenvatinib + pembrolizumabEisaiPhase 2
52
MORAb-004 (monoclonal antibody)EisaiPhase 2
52
Pembrolizumab + LenvatinibEisaiPhase 2
52
Lenvatinib + Lenvatinib + DacarbazineEisaiPhase 1/2
41

Other Products from IO Biotech

PD-L1 peptidePhase 2
44
PD-L1/IDO Peptide Vaccine + PembrolizumabPhase 1
25